ONCONEXT TissueTM genetic tests were planned for oncological use in order to detect somatic mutations, related to solid tumors, on tissue biopsy samples.
ONCONEXT TissueTM genetic tests TM employ the innovative Next Generation Sequencing (NGS) technology, which make it possible to detect, in an extremely sensitive way, the presence of somatic mutations even from a small amount of tumor tissue.
Simultaneous detection of different mutations allows to better understand the genomic profile of the tumor and to adopt the most suitable treatment.